Annual Accounts Payable
$2.43 M
-$2.88 M-54.27%
31 December 2023
Summary:
Ligand Pharmaceuticals Incorporated annual accounts payable is currently $2.43 million, with the most recent change of -$2.88 million (-54.27%) on 31 December 2023. During the last 3 years, it has fallen by -$1.36 million (-35.86%). LGND annual accounts payable is now -87.12% below its all-time high of $18.84 million, reached on 31 December 2003.LGND Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$4.69 M
+$2.90 M+161.80%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated quarterly accounts payable is currently $4.69 million, with the most recent change of +$2.90 million (+161.80%) on 30 September 2024. Over the past year, it has increased by +$2.22 million (+89.66%). LGND quarterly accounts payable is now -76.79% below its all-time high of $20.23 million, reached on 30 June 2004.LGND Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LGND Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -54.3% | +89.7% |
| 3 y3 years | -35.9% | -35.1% |
| 5 y5 years | -42.0% | +130.1% |
LGND Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -71.1% | at low | -75.5% | +161.8% |
| 5 y | 5 years | -71.1% | +0.3% | -75.5% | +161.8% |
| alltime | all time | -87.1% | +7.4% | -76.8% | +369.4% |
Ligand Pharmaceuticals Incorporated Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $4.69 M(+161.8%) |
| June 2024 | - | $1.79 M(-5.3%) |
| Mar 2024 | - | $1.89 M(-22.0%) |
| Dec 2023 | $2.43 M(-54.3%) | $2.43 M(-1.9%) |
| Sept 2023 | - | $2.48 M(-74.2%) |
| June 2023 | - | $9.58 M(+56.2%) |
| Mar 2023 | - | $6.13 M(+15.6%) |
| Dec 2022 | $5.31 M(-36.8%) | $5.31 M(-66.6%) |
| Sept 2022 | - | $15.89 M(-17.1%) |
| June 2022 | - | $19.15 M(+174.7%) |
| Mar 2022 | - | $6.97 M(-17.0%) |
| Dec 2021 | $8.40 M(+122.1%) | $8.40 M(+16.2%) |
| Sept 2021 | - | $7.23 M(-58.1%) |
| June 2021 | - | $17.27 M(+82.4%) |
| Mar 2021 | - | $9.47 M(+150.2%) |
| Dec 2020 | $3.78 M(+56.4%) | $3.78 M(-62.8%) |
| Sept 2020 | - | $10.17 M(+66.6%) |
| June 2020 | - | $6.10 M(+81.4%) |
| Mar 2020 | - | $3.37 M(+39.0%) |
| Dec 2019 | $2.42 M(-42.1%) | $2.42 M(+18.6%) |
| Sept 2019 | - | $2.04 M(-29.4%) |
| June 2019 | - | $2.89 M(-42.9%) |
| Mar 2019 | - | $5.06 M(+21.0%) |
| Dec 2018 | $4.18 M(+85.2%) | $4.18 M(+154.0%) |
| Sept 2018 | - | $1.65 M(-38.6%) |
| June 2018 | - | $2.68 M(-21.3%) |
| Mar 2018 | - | $3.41 M(+50.8%) |
| Dec 2017 | $2.26 M(-17.4%) | $2.26 M(-37.5%) |
| Sept 2017 | - | $3.62 M(+101.1%) |
| June 2017 | - | $1.80 M(-72.1%) |
| Mar 2017 | - | $6.46 M(+136.1%) |
| Dec 2016 | $2.73 M(-33.0%) | $2.73 M(-0.8%) |
| Sept 2016 | - | $2.76 M(+18.0%) |
| June 2016 | - | $2.34 M(-13.1%) |
| Mar 2016 | - | $2.69 M(-34.2%) |
| Dec 2015 | $4.08 M(-47.0%) | $4.08 M(+29.9%) |
| Sept 2015 | - | $3.14 M(+16.1%) |
| June 2015 | - | $2.71 M(-63.6%) |
| Mar 2015 | - | $7.44 M(-3.3%) |
| Dec 2014 | $7.70 M(+94.8%) | $7.70 M(+58.3%) |
| Sept 2014 | - | $4.86 M(-3.9%) |
| June 2014 | - | $5.06 M(+37.7%) |
| Mar 2014 | - | $3.67 M(-7.0%) |
| Dec 2013 | $3.95 M(-32.5%) | $3.95 M(-8.2%) |
| Sept 2013 | - | $4.30 M(-9.5%) |
| June 2013 | - | $4.75 M(-13.9%) |
| Mar 2013 | - | $5.52 M(-5.7%) |
| Dec 2012 | $5.85 M(-47.1%) | $5.85 M(-2.9%) |
| Sept 2012 | - | $6.03 M(-10.7%) |
| June 2012 | - | $6.75 M(-14.5%) |
| Mar 2012 | - | $7.89 M(-28.7%) |
| Dec 2011 | $11.06 M(+28.7%) | $11.06 M(+9.9%) |
| Sept 2011 | - | $10.07 M(-5.2%) |
| June 2011 | - | $10.63 M(-18.4%) |
| Mar 2011 | - | $13.03 M(+51.6%) |
| Dec 2010 | $8.60 M(-49.3%) | $8.60 M(-24.2%) |
| Sept 2010 | - | $11.34 M(-15.7%) |
| June 2010 | - | $13.45 M(-7.4%) |
| Mar 2010 | - | $14.52 M(-14.3%) |
| Dec 2009 | $16.95 M | $16.95 M(+17.8%) |
| Sept 2009 | - | $14.38 M(-3.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2009 | - | $14.84 M(-5.1%) |
| Mar 2009 | - | $15.64 M(+6.9%) |
| Dec 2008 | $14.63 M(+15.3%) | $14.63 M(+62.3%) |
| Sept 2008 | - | $9.01 M(-12.4%) |
| June 2008 | - | $10.29 M(-4.4%) |
| Mar 2008 | - | $10.76 M(-15.2%) |
| Dec 2007 | $12.68 M(+3.5%) | $12.68 M(+21.4%) |
| Sept 2007 | - | $10.45 M(-4.5%) |
| June 2007 | - | $10.94 M(-17.0%) |
| Mar 2007 | - | $13.18 M(+7.5%) |
| Dec 2006 | $12.26 M(-20.2%) | $12.26 M(-23.8%) |
| Sept 2006 | - | $16.08 M(-17.4%) |
| June 2006 | - | $19.46 M(+19.2%) |
| Mar 2006 | - | $16.32 M(+6.3%) |
| Dec 2005 | $15.36 M(-11.5%) | $15.36 M(+56.6%) |
| Sept 2005 | - | $9.81 M(-31.3%) |
| June 2005 | - | $14.28 M(-2.1%) |
| Mar 2005 | - | $14.59 M(-15.9%) |
| Dec 2004 | $17.35 M(-7.9%) | $17.35 M(+3.8%) |
| Sept 2004 | - | $16.72 M(-17.3%) |
| June 2004 | - | $20.23 M(+19.9%) |
| Mar 2004 | - | $16.87 M(-10.5%) |
| Dec 2003 | $18.84 M(+57.3%) | $18.84 M(+9.2%) |
| Sept 2003 | - | $17.26 M(+59.5%) |
| June 2003 | - | $10.82 M(-19.5%) |
| Mar 2003 | - | $13.44 M(+12.2%) |
| Dec 2002 | $11.98 M(+122.5%) | $11.98 M(+24.0%) |
| Sept 2002 | - | $9.66 M(-3.6%) |
| June 2002 | - | $10.03 M(+42.6%) |
| Mar 2002 | - | $7.03 M(+30.6%) |
| Dec 2001 | $5.38 M(+40.7%) | $5.38 M(+21.9%) |
| Sept 2001 | - | $4.42 M(+7.5%) |
| June 2001 | - | $4.11 M(+5.7%) |
| Mar 2001 | - | $3.89 M(+1.6%) |
| Dec 2000 | $3.83 M(-29.1%) | $3.83 M(-14.1%) |
| Sept 2000 | - | $4.46 M(-12.0%) |
| June 2000 | - | $5.07 M(+5.0%) |
| Mar 2000 | - | $4.82 M(-10.7%) |
| Dec 1999 | $5.40 M(-56.5%) | $5.40 M(-1.8%) |
| Sept 1999 | - | $5.50 M(-27.6%) |
| June 1999 | - | $7.60 M(+7.0%) |
| Mar 1999 | - | $7.10 M(-42.7%) |
| Dec 1998 | $12.40 M(+15.9%) | $12.40 M(+125.5%) |
| Sept 1998 | - | $5.50 M(-24.7%) |
| June 1998 | - | $7.30 M(+78.0%) |
| Mar 1998 | - | $4.10 M(-61.7%) |
| Dec 1997 | $10.70 M(+161.0%) | $10.70 M(+197.2%) |
| Sept 1997 | - | $3.60 M(+12.5%) |
| June 1997 | - | $3.20 M(-8.6%) |
| Mar 1997 | - | $3.50 M(-14.6%) |
| Dec 1996 | $4.10 M(+5.1%) | $4.10 M(+141.2%) |
| Sept 1996 | - | $1.70 M(-29.2%) |
| June 1996 | - | $2.40 M(+41.2%) |
| Mar 1996 | - | $1.70 M(-56.4%) |
| Dec 1995 | $3.90 M(+69.6%) | $3.90 M(+85.7%) |
| Sept 1995 | - | $2.10 M(+110.0%) |
| Mar 1995 | - | $1.00 M(-56.5%) |
| Dec 1994 | $2.30 M | $2.30 M(+91.7%) |
| Sept 1994 | - | $1.20 M(-7.7%) |
| June 1994 | - | $1.30 M(+30.0%) |
| Mar 1994 | - | $1.00 M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual accounts payable?
- What is the all time high annual accounts payable for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual accounts payable year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly accounts payable?
- What is the all time high quarterly accounts payable for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly accounts payable year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual accounts payable?
The current annual accounts payable of LGND is $2.43 M
What is the all time high annual accounts payable for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual accounts payable is $18.84 M
What is Ligand Pharmaceuticals Incorporated annual accounts payable year-on-year change?
Over the past year, LGND annual accounts payable has changed by -$2.88 M (-54.27%)
What is Ligand Pharmaceuticals Incorporated quarterly accounts payable?
The current quarterly accounts payable of LGND is $4.69 M
What is the all time high quarterly accounts payable for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly accounts payable is $20.23 M
What is Ligand Pharmaceuticals Incorporated quarterly accounts payable year-on-year change?
Over the past year, LGND quarterly accounts payable has changed by +$2.22 M (+89.66%)